- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03974854
Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma (ALIX)
Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma (ALIX)
Current standard of care for patients with metastatic Pancreatic Ductal AdenoCarcinoma (PDAC) is chemotherapy, preferential regimen being FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin). Due to more hematologic (neutropenia) and gastrointestinal toxicities, FOLFIRINOX is only administered in fit patients (age < 75 years, ECOG Performance status 0-1, and bilirubin < 1.5 ULN).
However, elderly or frail patients represent more than half of patients with PDAC and are treated with gemcitabine monochemotherapy. Maintaining more than one drug (polychemotherapy) may improve survival and quality of life in this population.
ALIX is a non-comparative randomized 2:1 phase II study. This study will assess the efficacy and safety of the polychemotherapy with XELOXIRI-3 versus gemcitabine as first-line chemotherapy in elderly or frail patients with locally advanced or metastatic PDAC.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Angélique Dr VIENOT
- Phone Number: +33381479999
- Email: a3vienot@chu-besancon.fr
Study Contact Backup
- Name: Marion JACQUIN
- Email: m1jacquin@chu-besancon.fr
Study Locations
-
-
-
Besancon, France
- University Hospital of Besancon
-
Montbéliard, France
- Hôpital Nord Franche-Comté
-
Mulhouse, France
- CH Mulhouse
-
Nancy, France
- CHU Nancy
-
Reims, France
- CHU Reims
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Main Inclusion Criteria :
- Histologically proven pancreatic ductal adenocarcinoma
- Locally Advanced or metastatic disease
- Measurable disease according to RECIST v1.1 criteria
- Age ≥ 75 years;
OR age between 65 and 75 years AND with at least one frailty contraindication to the administration of chemotherapy with FOLFIRINOX:
- Eastern Cooperative Oncology Group Performance status (ECOG-PS) 2
- Total serum bilirubin > 1.5 ULN (biliary drainage allowed)
- Clinico-biological frailty criteria:
- weight loss > 10% in 6 months or > 5% in 1 month
- or body mass index (BMI) ≤ 21
- or serum albumin < 30 g/L
or ADL (Activities of Daily Living) score < 6
- Eligible for gemcitabine as first-line chemotherapy
- Registration in a national health care system
- Written informed consent obtained from the patient prior to performing any protocol-related procedures
Main Exclusion Criteria:
- Age < 65 years
- Localized non-metastatic cancer
- ECOG-PS 3-4
- Previous treatment For advanced stage (locally advanced or metastatic): chemotherapy, radiochemotherapy; For localized stage: FOLFIRINOX chemotherapy (neoadjuvant or adjuvant); adjuvant chemotherapy with gemcitabine before relapse is permitted (provide it has been administered more than 6 months before)
- Uncontrolled intercurrent cardiovascular disease
- Known or suspected allergy or hypersensitivity to any of the study drugs (capecitabine, oxaliplatin, irinotecan, gemcitabine)
- Bowel obstruction or sub-obstruction or impossible oral treatment
- Prior peripheral neuropathy of grade ≥ 2
- Known complete dihydropyrimidine dehydrogenase (DPD) or UDP-glycosyltransferase 1 polypeptide A1 (UGT1A1) deficiency
- Inadequate hematological, hepatic, and renal functions
- Psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs (Adverse Events) or compromise the ability of the patient to give written informed consent
- Tutelage or guardianship
- Diagnosis of any second malignancy within the last 2 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix uteri
- Current participation in another clinical trial using therapeutic experimental agents
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A: XELOXIRI-3
capecitabine 625 mg/m2 twice daily on days 1-7 oxaliplatine 85 mg/m2 on Day 1 irinotecan 90 mg/m2 on Day 3, every 14 days
|
chemotherapy with XELOXIRI-3 regimen
Other Names:
|
Active Comparator: Arm B: Gemcitabine
1000 mg / m2 on D1, D8 and D15, every 28 days
|
chemotherapy with Gemcitabine regimen
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
6 months Progression-Free Survival (PFS) rate
Time Frame: 6 months after the date of initiation of treatment (1st day of 1st cycle of chemotherapy)
|
6 months after the date of initiation of treatment (1st day of 1st cycle of chemotherapy)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Angélique VIENOT, Dr, University Hospital of Besancon
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Topoisomerase Inhibitors
- Topoisomerase I Inhibitors
- Capecitabine
- Irinotecan
- Gemcitabine
Other Study ID Numbers
- P/2018/395
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Pancreatic Adenocarcinoma
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
Georgetown UniversityNational Cancer Institute (NCI); Mayo Clinic; Emory University; Indiana University and other collaboratorsTerminatedMetastatic Colorectal Cancer | Pancreatic Adenocarcinoma | Colorectal Adenocarcinoma | Metastatic Pancreatic CancerUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal AdenocarcinomaUnited States
-
Georgetown UniversityERYtech PharmaActive, not recruitingMetastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal Adenocarcinoma | Primary Pancreatic Ductal AdenocarcinomaUnited States
-
Translational Genomics Research InstituteMerck Sharp & Dohme LLC; Stand Up To CancerCompletedPancreatic Cancer | Pancreas Adenocarcinoma | Metastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic Cancer | Advanced Pancreatic CancerUnited States
-
Scandion Oncology A/SAlcedis GmbHRecruitingMetastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Inoperable Disease | Localized Pancreatic AdenocarcinomaDenmark, Germany
-
Mayo ClinicNovoCure Ltd.RecruitingPancreatic Adenocarcinoma | Pancreas Cancer | Metastatic Pancreatic Cancer | Metastatic AdenocarcinomaUnited States
-
Colin D. Weekes, M.D., PhDActuate Therapeutics Inc.; Lustgarten FoundationRecruitingPancreatic Adenocarcinoma | Pancreatic Adenocarcinoma MetastaticUnited States
-
Jean-Luc Van LaethemCelgene CorporationCompletedPancreatic Adenocarcinoma Resectable | Pancreatic Adenocarcinoma Metastatic | Pancreatic Adenocarcinoma Locally AdvancedBelgium
Clinical Trials on XELOXIRI-3
-
Eastern Mediterranean UniversityCompletedOverweight and ObesityCyprus
-
Edwards LifesciencesActive, not recruitingHeart Diseases | Aortic Stenosis, SevereUnited States, Canada
-
Third Affiliated Hospital, Sun Yat-Sen UniversityUnknown
-
Edwards LifesciencesActive, not recruitingAortic Valve Stenosis | Aortic Stenosis, CalcificUnited States, Australia, Japan, Canada, Netherlands, Switzerland
-
University of AarhusSteno Diabetes Center Aarhus, Aarhus University Hospital, Denmark; Department...CompletedKetosis | Postprandial Hyperglycemia | Glucose Metabolism Disorders (Including Diabetes Mellitus)Denmark
-
Edwards LifesciencesRecruitingPulmonary Valve Insufficiency | Complex Congenital Heart Defect | Dysfunctional RVOT Conduit | Pulmonary Valve DegenerationUnited States
-
Sheffield Children's NHS Foundation TrustUniversity of SheffieldCompletedAcute BronchiolitisUnited Kingdom
-
UNICANCERCompleted
-
University of Massachusetts, WorcesterWithdrawn